Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 21821334)

1.

[Efficacy of mycophenolate associated with methotrexate as a maintenance treatment for systemic sclerosis-associated interstitial lung disease].

Gonzalez-Nieto JA, Martin-Suarez IJ, Gil-Muñoz FL.

Arch Bronconeumol. 2011 Nov;47(11):575. doi: 10.1016/j.arbres.2011.06.007. Epub 2011 Aug 6. Spanish. No abstract available.

2.

Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.

Fathi N, Furst DE, Clements PJ.

Curr Rheumatol Rep. 2007 May;9(2):144-50.

PMID:
17502045
3.

Immunosuppression for interstitial lung disease in systemic sclerosis.

Cappelli S, Guiducci S, Bellando Randone S, Matucci Cerinic M.

Eur Respir Rev. 2013 Sep 1;22(129):236-43. doi: 10.1183/09059180.00001813. Review.

4.

Unusual association of systemic sclerosis and ankylosing spondylitis.

Soledade CS, Sampaio-Barros PD, Samara AM, Marques-Neto JF.

Clin Rheumatol. 2005 Nov;24(6):652-4. Epub 2004 Aug 27. No abstract available.

PMID:
15338450
5.

Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis.

Espinosa G, Simeón CP, Plasín MÁ, Xaubet A, Muñoz X, Fonollosa V, Cervera R, Vilardell M.

Arch Bronconeumol. 2011 May;47(5):239-45. doi: 10.1016/j.arbres.2011.01.010. Epub 2011 Mar 31. English, Spanish.

6.

Advances in immunosuppressive therapy.

Marder W, McCune WJ.

Semin Respir Crit Care Med. 2007 Aug;28(4):398-417. Review.

PMID:
17764058
7.

Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP.

Curr Rheumatol Rep. 2009 Apr;11(2):111-9. Review.

PMID:
19296883
8.

High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.

Wanchu A, Suryanaryana BS, Sharma S, Sharma A, Bambery P.

Int J Rheum Dis. 2009 Sep;12(3):239-42. doi: 10.1111/j.1756-185X.2009.01417.x.

PMID:
20374353
9.

Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies.

Nannini C, West CP, Erwin PJ, Matteson EL.

Arthritis Res Ther. 2008;10(5):R124. doi: 10.1186/ar2534. Epub 2008 Oct 20. Review. Erratum in: Arthritis Res Ther. 2009;11(2):408.

10.

Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis.

Vallance DK, Lynch JP 3rd, McCune WJ.

Curr Opin Rheumatol. 1995 May;7(3):174-82. Review.

PMID:
7612408
11.

Cyclophosphamide in scleroderma lung disease.

Sullivan KM, McSweeney PA, Nash RA.

N Engl J Med. 2006 Sep 14;355(11):1173-4; author reply 1174. No abstract available.

PMID:
16977701
12.

A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.

Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, Zubair M, Rivera V.

Rheumatology (Oxford). 2009 Jan;48(1):49-52. doi: 10.1093/rheumatology/ken369. Epub 2008 Sep 24.

13.

Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis?

Pérez Campos D, Estévez Del Toro M, Peña Casanovas A, González Rojas PP, Morales Sánchez L, Gutiérrez Rojas AR.

Reumatol Clin. 2012 Mar-Apr;8(2):58-62. doi: 10.1016/j.reuma.2011.11.006. Epub 2012 Feb 7.

14.

Cyclophosphamide in scleroderma lung disease.

Andreu JL, Silva L.

N Engl J Med. 2006 Sep 14;355(11):1173; author reply 1174. No abstract available.

PMID:
16977700
15.

[Interstitial lung disease in systemic sclerosis].

Mouthon L, Berezné A, Brauner M, Kambouchner M, Guillevin L, Valeyre D.

Presse Med. 2006 Dec;35(12 Pt 2):1943-51. Review. French.

PMID:
17159721
16.

Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide.

Abhishek A, Yazdani R, Pearce F, Regan M, Lim K, Hubbard R, Lanyon P.

Clin Rheumatol. 2011 Aug;30(8):1099-104. doi: 10.1007/s10067-011-1734-1. Epub 2011 Apr 12.

PMID:
21484227
17.

Cyclophosphamide for scleroderma lung disease.

Martinez FJ, McCune WJ.

N Engl J Med. 2006 Jun 22;354(25):2707-9. No abstract available.

PMID:
16790705
18.

Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?

Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L.

Ann N Y Acad Sci. 2007 Sep;1110:271-84.

PMID:
17911442
19.

Cyclophosphamide in scleroderma lung disease.

Kuschner WG.

N Engl J Med. 2006 Sep 14;355(11):1173; author reply 1174. No abstract available.

20.

David against Goliath: may we target and defeat interstitial lung disease in systemic sclerosis?

Miniati I, Conforti ML, Guiducci S, Matucci Cerinic M.

Clin Exp Rheumatol. 2007 Mar-Apr;25(2):169-71. No abstract available.

PMID:
17543137
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk